Pfizer: COVID-19 vaccine testing shows 95 percent efficacy, emergency use application planned ‘within days’

The Hill logo

Pfizer on Wednesday announced that final data on its coronavirus vaccine candidate showed it to be 95 percent effective, adding that the company would be applying for Federal Drug Administration (FDA) emergency authorization “within days.” 

Pfizer said that the vaccine candidate, developed with German company BioNTech, is 95 percent effective “against COVID-19 beginning 28 days after the first dose.” 

The company last week said that interim data revealed its vaccine to be 90 percent effective.  Continue reading.